IgG-Mediated Anaphylaxis to a Synthetic Long Peptide Vaccine Containing a B Cell Epitope Can Be Avoided by Slow-Release Formulation.
- Resource Type
- Article
- Authors
- Quakkelaar, Esther D.; Fransen, Marieke F.; van Maren, Wendy W. C.; Vaneman, Joost; Loof, Nikki M.; van Heiningen, Sandra H.; Verbeek, J. Sjef; Ossendorp, Ferry; Melief, Cornelis J. M.
- Source
- Journal of Immunology. 6/15/2014, Vol. 192 Issue 12, p5813-5820. 8p.
- Subject
- *PEPTIDES
*B cells
*T cells
*INFECTION
*TUMORS
- Language
- ISSN
- 0022-1767
Synthetic long peptides (SLP) are a promising vaccine modality to induce therapeutic T cell responses in patients with chronic infections and tumors. We studied different vaccine formulations in mice using SLP derived from carcinoembryonic Ag. We discovered that one of the SLP contains a linear Ab epitope in combination with a CD4 epitope. Repeated vaccination with this carcinoembryonic Ag SLP in mice shows improved T cell responses and simultaneously induced high titers of peptide-specific Abs. These Abs resulted in unexpected anaphylaxis after a third or subsequent vaccinations with the SLP when formulated in saline. Administration of low SLP doses in the slow-release vehicle IFA prevented the anaphylaxis after repeated vaccination. This study underscores both the immunogenicity of SLP vaccination, for inducing T cell as well as B cell responses, and the necessity of safe administration routes. [ABSTRACT FROM AUTHOR]